Xiao Xu

ACEA Therapeutics Inc.

San Diego, CA

United States

SCHOLARLY PAPERS

2

DOWNLOADS

40

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (2)

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

Number of pages: 37 Posted: 28 Jan 2019
Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences
Downloads 16 (620,791)

Abstract:

Loading...

Abivertinib, resistance, EGFR amplification

The Resistance Landscape of Abivertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, and Clinical Strategy to Overcome Resistance in EGFR T790M-Positive Non-Small Cell Lung Cancer

Number of pages: 38 Posted: 01 Mar 2019
Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Burning Rock Biotech, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute, Guangdong Academy of Medical Sciences, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc., Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute and Guangdong Academy of Medical Sciences
Downloads 12 (651,292)

Abstract:

Loading...

EGFR; T790M; abivertinib; resistance; NSCLC

2.

A Modified Phase 1 Clinical Trial of Abivertinib (Ac0010), a Third-Generation EGFR Tyrosine Kinase Inhibitor, in Chinese Patients with EGFR-T790M-positive Non-Small Cell Lung Cancer

Number of pages: 29 Posted: 06 Dec 2018
Government of the People's Republic of China - 307th Hospital, Government of the People's Republic of China - 307th Hospital, Chinese Academy of Medical Sciences, Zhejiang University, Chinese Academy of Medical Sciences, Central South University, Peking University - Cancer Hospital and Institute, Jilin Province Cancer Hospital, Chinese Academy of Medical Sciences, Guangdong Academy of Medical Sciences, Guangdong Academy of Medical Sciences, ACEA Pharmaceutical Research, ACEA Therapeutics Inc., ACEA Therapeutics Inc., ACEA Therapeutics Inc. and Guangdong Academy of Medical Sciences - Guangdong Lung Cancer Institute
Downloads 12 (626,419)

Abstract:

Loading...

abivertinib; AC0010; EGFR; NSCLC; T790M; Phase 1